MoneyWorks4Me

Novartis India launches precision radiotherapy ‘Pluvicto’ for prostate cancer

15 Jun 2026 Evaluate

Novartis India has launched Pluvicto, a precision radiotherapy for prostate cancer.  Pluvicto is the country's first regulatory authority-approved radioligand therapy for eligible patients with prostate-specific membrane antigen (PSMA)-positive prostate cancer. 

Designed to precisely target prostate cancer cells while minimising exposure to healthy tissues, Pluvicto introduces a new treatment approach for metastatic prostate cancer, a disease that continues to place a significant physical and emotional burden on patients and families across India. 

Novartis India is a pharmaceutical company. The business operations of the Company include Pharmaceuticals, Generic, over the counter (OTC) and Animal Health.

Novartis India Share Price

1596.85 45.75 (2.95%)
14-Aug-2026 14:40 View Price Chart
Peers
Company Name CMP
Redington 335.50
Amrapali Industries 36.65
Adani Enterprises 3030.00
Rashi Peripheral 835.95
PDS 371.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: